Top Medtech Companies in the UK

From AI-powered diagnostics to next-generation surgical robotics and novel drug delivery systems, UK medtech companies are tackling some of the most pressing medical challenges of our time.

In 2023, the Department of Health and Social Care launched its first-ever Medical Technology Strategy, underlining the government’s commitment to supporting medtech innovation and scaling adoption across the NHS. Since then, funding has continued to flow into the sector, and private companies are playing a central role in shaping the future of healthcare.

In this article, we explore the top 10 medtech companies in the UK, ranked by the total amount of equity investment raised to date. All companies featured have raised investment between 1 June 2020 and July 2025.

What is medtech?

Medtech — short for medical technology — refers to any technology designed to support the prevention, diagnosis, monitoring, or treatment of health conditions. It covers a wide spectrum of tools and devices, from wearable monitors and imaging equipment to surgical robots and AI-driven drug design platforms.

In recent years, the term has become increasingly associated with high-tech, next-generation innovations that aim to improve clinical outcomes and enhance the patient experience. Today’s medtech solutions are helping to detect disease earlier, enable more personalised treatment, and streamline care delivery at scale.

The UK has long been a global leader in medical innovation. From the invention of the MRI scanner to advances in sequencing and diagnostics, the country’s universities, research centres, and startups have played a pivotal role in shaping the industry. Ongoing government support, strategic investment, and cross-sector collaboration continue to fuel the UK’s dynamic medtech ecosystem.

Medtech vs healthtech: What’s the difference?

While the two terms are often used interchangeably, there are clear distinctions between medtech and healthtech.

Medtech typically refers to physical medical devices and technologies used in clinical or hospital settings, such as diagnostic tools, surgical equipment, or implantable devices. These products often require rigorous clinical validation and regulatory approval before being adopted by healthcare providers.

Healthtech, on the other hand, covers digital technologies aimed at improving the broader healthcare experience. This includes mobile health apps, wearable trackers, telehealth platforms, and digital infrastructure for care delivery and payments.

In short: healthtech improves how we access and manage healthcare, while medtech transforms the tools used in diagnosis and treatment. Both are critical to the future of healthcare, operating in distinct parts of the system.

A comment on the UK healthtech market in 2025

While this article focuses on medtech, healthtech continues to gain momentum — and the two sectors are often analysed in tandem. As of Q1 2025, UK healthtech and life sciences startups raised $1.8b in venture capital — the sector’s second strongest quarter on record. Half of that capital was directed to AI-first ventures, led by major deals for Isomorphic Labs ($600m) and Verdiva Bio ($411m).

By the end of 2024, the UK’s top 1,000 healthtech startups had collectively raised £27.4 billion and reached valuations of £32b, with roughly £865m in grant support and nearly 30,000 employees across the ecosystem.

Despite a slowdown in new unicorn creation — just three minted in 2024 — the UK still houses 41 active unicorns, including prominent healthtech businesses like Cera. Cera itself continues to scale: in 2025 it surpassed $500 million in annualised revenues, delivering care in patients’ homes and using predictive tech to cut hospitalisation rates by over 50%.

But with growth comes challenge. Recent analysis underscores concerns around the UK’s drug pricing regime and regulatory hurdles that risk eroding competitiveness, particularly relative to more agile markets like China and the US.

Still, the fundamentals of the UK ecosystem remain strong. Global talent, world-class research institutions, direct links to the NHS, and continued investor demand. In 2023 alone, 41% of all European life sciences VC flowed into UK companies.

Trends in the UK’s medtech sector

The UK’s medtech landscape is thriving, with notable clusters forming across the country, but the south continues to lead the way. London is home to the largest concentration of medtech companies, with 3,492 businesses tracked to date. It’s followed by the South East (2,124) and the East of England (1,579), making these regions key hubs for innovation in medical technologies.

Academic spinouts play a significant role in fuelling the sector. There are now 875 medtech companies that have spun out of academic institutions, with the highest numbers based in the South East (151), East of England (137), and London (171). Scotland also makes a strong showing, with 97 spinouts. Leading universities for medtech spinouts include the University of Oxford, University of Cambridge, Imperial College London, and University College London.

Medtech companies are typically early-stage, with 36.4% currently operating at the seed stage and 24.5% at the venture stage. Just 8.2% have reached the growth stage, reflecting the sector’s continuous pipeline of emerging startups with high innovation potential.

Subsector trends show that pharmaceuticals dominate the field, making up 52.3% of all medtech companies. This is followed by medical devices and instruments (27.2%) and clinical diagnostics (13.3%), pointing to a strong focus on therapeutic development, as well as tools for diagnosis and treatment.

However, gender diversity remains a challenge for the sector. Over half (57.3%) of UK medtech companies have all-male director teams, with only 12% led by all-female boards. A further 14.4% have gender-equal leadership, while 14.7% have a majority-male board. Although there are signs of improvement, these figures highlight the need for continued efforts to support more diverse leadership in the industry.

Medtech investment

UK medtech continues to attract substantial investor interest, particularly at the early stages. Since 2005, there have been 6,821 equity fundraisings involving medtech companies, collectively worth £34.2b. Notably, the majority of these investments (over 80%) were directed at seed and venture-stage businesses, underlining the sector’s appeal to investors seeking early-stage innovation.

Investment activity has remained strong over the past four years, with 708 fundraisings worth £4.89b in 2024 alone. Other high points include 676 deals in 2021 (£4.38b) and 691 in 2023 (£2.17b). While funding values may fluctuate year-on-year, the underlying trend is clear: medtech remains a key focus area for UK venture capital and public sector funding alike.

The number of active medtech companies in the UK has grown by 204% over the last decade, reflecting not only investor appetite but also increasing commercial traction, academic spinout activity, and adoption within the NHS and global healthcare markets.
Some of the most prolific backers in the space include:

By number of fundraisings:

• Scottish Venture Fund – 131
• Scottish Co-Investment Fund – 123
• UK Innovation & Science Seed Fund (UKI2S) – 107
• Oxford Technology – 92
• Cambridge Angels – 89

By total value of fundraisings:

• Cambridge Innovation Capital – £1.67b
• Forbion Capital Partners – £1.66b
• IP Group – £1.43b
• Oxford Science Enterprises – £1.33b

The UK’s top medtech companies

The future of medtech companies in the UK

The future of UK medtech is bright, and fast-moving. From AI-assisted diagnostics to robotic surgery and next-generation drug discovery, British medtech companies are driving innovation at every stage of the healthcare journey. With record levels of investment, international expansion, and new product approvals, the sector is maturing rapidly while continuing to break new ground.

Emerging technologies such as precision radiopharmaceuticals, advanced sequencing, and AI-led drug design are consistently being developed, trialled, and deployed by UK companies right now. The integration of data-driven platforms and remote monitoring tools is also helping reshape how healthcare is delivered, making it more personalised, accessible, and efficient.

Backed by strong academic institutions, world-class talent, and a supportive funding landscape, the UK is well-positioned to remain a global medtech hub. As challenges in public health and care delivery continue to evolve, medtech companies will be central to providing smarter, faster, and more scalable solutions.

Working with Beauhurst

Want to dig deeper into the UK’s medtech landscape? The BeauhurstInvest platform gives you instant access to the most up-to-date data on the country’s most exciting businesses.

Track company growth, funding history, acquisitions, and more, plus download investor lists, analyse sector trends, and export charts and reports in just a few clicks. Whether you’re scouting investment opportunities, mapping the ecosystem, or identifying collaboration partners, Beauhurst can help you stay ahead of the curve.

To find out more, take a tour of the platform or book a personalised demo below.